A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Latest Information Update: 10 Mar 2025
At a glance
- Drugs BHV-7000 (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceuticals
Most Recent Events
- 05 Mar 2025 Status changed from active, no longer recruiting to completed.
- 16 Dec 2024 According to the Biohaven Therapeutics Media Release, company eagerly anticipate topline results.
- 16 Dec 2024 According to the Biohaven Therapeutics Media Release, company announced the completion of enrollment in in 4Q 2024.